Answer
Jun 11, 2026 - 08:25 AM
It works by inhibiting the abnormal proteins produced by the BCR-ABL gene, which are responsible for the uncontrolled growth of malignant cells in CML and Ph+ ALL. BCR-ABL is a fusion gene found in these cancers, and targeting it helps prevent cancer cells from multiplying. This targeted mechanism allows for more effective management of leukemia.
